Copyright Reports & Markets. All rights reserved.

Global Gastrointestinal Stromal Tumor (GIST) Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Gastrointestinal Stromal Tumor (GIST) Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by Product
      • 1.4.2 Amcasertib
      • 1.4.3 Anagrelide hydrochloride CR
      • 1.4.4 APG-1351
      • 1.4.5 Binimetinib
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size
      • 2.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2014-2025
      • 2.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales 2014-2025
    • 2.2 Gastrointestinal Stromal Tumor (GIST) Drug Growth Rate by Regions
      • 2.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Regions
      • 2.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Gastrointestinal Stromal Tumor (GIST) Drug Sales by Manufacturers
      • 3.1.1 Gastrointestinal Stromal Tumor (GIST) Drug Sales by Manufacturers
      • 3.1.2 Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Manufacturers
      • 3.2.1 Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Gastrointestinal Stromal Tumor (GIST) Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Gastrointestinal Stromal Tumor (GIST) Drug Price by Manufacturers
    • 3.4 Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Gastrointestinal Stromal Tumor (GIST) Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Gastrointestinal Stromal Tumor (GIST) Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Gastrointestinal Stromal Tumor (GIST) Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Product
    • 4.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Product
    • 4.3 Gastrointestinal Stromal Tumor (GIST) Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 6.1.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 6.1.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 6.3 North America Gastrointestinal Stromal Tumor (GIST) Drug by End User

    7 Europe

    • 7.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 7.1.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 7.1.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 7.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 8.1.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 8.1.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 8.3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug by End User

    9 Central & South America

    • 9.1 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 9.1.1 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 9.1.2 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 9.3 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug by Countries
      • 10.1.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries
      • 10.1.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug by Product
    • 10.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug by End User

    11 Company Profiles

    • 11.1 Ariad Pharmaceuticals, Inc.
      • 11.1.1 Ariad Pharmaceuticals, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.1.5 Ariad Pharmaceuticals, Inc. Recent Development
    • 11.2 Arog Pharmaceuticals, Inc.
      • 11.2.1 Arog Pharmaceuticals, Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.2.5 Arog Pharmaceuticals, Inc. Recent Development
    • 11.3 Array BioPharma Inc.
      • 11.3.1 Array BioPharma Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.3.5 Array BioPharma Inc. Recent Development
    • 11.4 Astex Pharmaceuticals, Inc.
      • 11.4.1 Astex Pharmaceuticals, Inc. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.4.5 Astex Pharmaceuticals, Inc. Recent Development
    • 11.5 Blueprint Medicines Corporation
      • 11.5.1 Blueprint Medicines Corporation Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.5.5 Blueprint Medicines Corporation Recent Development
    • 11.6 Boston Biomedical, Inc.
      • 11.6.1 Boston Biomedical, Inc. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.6.5 Boston Biomedical, Inc. Recent Development
    • 11.7 Calithera Biosciences, Inc.
      • 11.7.1 Calithera Biosciences, Inc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.7.5 Calithera Biosciences, Inc. Recent Development
    • 11.8 Chipscreen Biosciences Ltd
      • 11.8.1 Chipscreen Biosciences Ltd Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.8.5 Chipscreen Biosciences Ltd Recent Development
    • 11.9 Deciphera Pharmaceuticals, LLC
      • 11.9.1 Deciphera Pharmaceuticals, LLC Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.9.5 Deciphera Pharmaceuticals, LLC Recent Development
    • 11.10 F. Hoffmann-La Roche Ltd.
      • 11.10.1 F. Hoffmann-La Roche Ltd. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Products Offered
      • 11.10.5 F. Hoffmann-La Roche Ltd. Recent Development
    • 11.11 Horizon Pharma Plc
    • 11.12 Immunicum AB
    • 11.13 Jiangsu Hengrui Medicine Co., Ltd.
    • 11.14 Kolltan Pharmaceuticals, Inc.
    • 11.15 Natco Pharma Limited
    • 11.16 Nerviano Medical Sciences S.r.l.
    • 11.17 Novartis AG
    • 11.18 Omeros Corporation

    12 Future Forecast

    • 12.1 Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast by Regions
      • 12.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast by Product
      • 12.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Forecast by Product 2019-2025
    • 12.3 Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast by End User
    • 12.4 North America Gastrointestinal Stromal Tumor (GIST) Drug Forecast
    • 12.5 Europe Gastrointestinal Stromal Tumor (GIST) Drug Forecast
    • 12.6 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Forecast
    • 12.7 Central & South America Gastrointestinal Stromal Tumor (GIST) Drug Forecast
    • 12.8 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Gastrointestinal Stromal Tumor (GIST) Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Gastrointestinal Stromal Tumor (GIST) Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Gastrointestinal Stromal Tumor (GIST) Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Gastrointestinal Stromal Tumor (GIST) Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gastrointestinal Stromal Tumor (GIST) Drug in these regions.
      This research report categorizes the global Gastrointestinal Stromal Tumor (GIST) Drug market by top players/brands, region, type and end user. This report also studies the global Gastrointestinal Stromal Tumor (GIST) Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Ariad Pharmaceuticals, Inc.
      Arog Pharmaceuticals, Inc.
      Array BioPharma Inc.
      Astex Pharmaceuticals, Inc.
      Blueprint Medicines Corporation
      Boston Biomedical, Inc.
      Calithera Biosciences, Inc.
      Chipscreen Biosciences Ltd
      Deciphera Pharmaceuticals, LLC
      F. Hoffmann-La Roche Ltd.
      Horizon Pharma Plc
      Immunicum AB
      Jiangsu Hengrui Medicine Co., Ltd.
      Kolltan Pharmaceuticals, Inc.
      Natco Pharma Limited
      Nerviano Medical Sciences S.r.l.
      Novartis AG
      Omeros Corporation

      Market size by Product
      Amcasertib
      Anagrelide hydrochloride CR
      APG-1351
      Binimetinib
      Others
      Market size by End User
      Clinic
      Hospital
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Gastrointestinal Stromal Tumor (GIST) Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Gastrointestinal Stromal Tumor (GIST) Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Gastrointestinal Stromal Tumor (GIST) Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Gastrointestinal Stromal Tumor (GIST) Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Gastrointestinal Stromal Tumor (GIST) Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Gastrointestinal Stromal Tumor (GIST) Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now